首页> 外文OA文献 >Genome-wide association study for ovarian cancer susceptibility using pooled DNA
【2h】

Genome-wide association study for ovarian cancer susceptibility using pooled DNA

机译:使用汇集的DNA进行的全基因组卵巢癌敏感性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent Genome-Wide Association Studies (GWAS) have identified four low-penetrance ovarian cancer susceptibility loci. We hypothesized that further moderate- or low-penetrance variants exist among the subset of single-nucleotide polymorphisms (SNPs) not well tagged by the genotyping arrays used in the previous studies, which would account for some of the remaining risk. We therefore conducted a time- and cost-effective stage 1 GWAS on 342 invasive serous cases and 643 controls genotyped on pooled DNA using the high-density Illumina 1M-Duo array. We followed up 20 of the most significantly associated SNPs, which are not well tagged by the lower density arrays used by the published GWAS, and genotyping them on individual DNA. Most of the top 20 SNPs were clearly validated by individually genotyping the samples used in the pools. However, none of the 20 SNPs replicated when tested for association in a much larger stage 2 set of 4,651 cases and 6,966 controls from the Ovarian Cancer Association Consortium. Given that most of the top 20 SNPs from pooling were validated in the same samples by individual genotyping, the lack of replication is likely to be due to the relatively small sample size in our stage 1 GWAS rather than due to problems with the pooling approach. We conclude that there are unlikely to be any moderate or large effects on ovarian cancer risk untagged by less dense arrays. However, our study lacked power to make clear statements on the existence of hitherto untagged small-effect variants.
机译:最近的全基因组关联研究(GWAS)已经确定了四个低渗透性卵巢癌易感基因座。我们假设在先前研究中使用的基因分型阵列未很好标记的单核苷酸多态性(SNP)子集中还存在其他中等或低渗透性变异,这将解释一些尚存的风险。因此,我们使用高密度Illumina 1M-Duo阵列对342例侵袭性浆液病例和643个基因型进行了时间和成本效益的1 GWAS合并基因组DNA分型。我们跟踪了20个最显着相关的SNP,这些SNP没有被已发表的GWAS使用的低密度阵列很好地标记,并在单个DNA上对它们进行基因分型。通过对样本库中使用的样本进行单独的基因分型,可以清楚地验证前20个SNP中的大多数。但是,在来自卵巢癌协会联合会的更大的第2阶段的4,651例病例和6,966例对照的关联中测试时,没有20种SNP能够复制。鉴于来自合并的前20个SNP中的大多数已通过个体基因分型在同一样本中得到验证,因此缺乏复制很可能是由于我们第一阶段GWAS中的样本量相对较小,而不是归因于合并方法的问题。我们得出的结论是,密度较小的阵列对卵巢癌风险的影响不会有中等或较大的影响。但是,我们的研究缺乏对迄今未标记的小效应变体的存在做出清晰陈述的能力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号